1601 TRAPELO ROAD, WALTHAM, MA
Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
Invivyd, Inc. Elects New Directors at Annual Meeting of Stockholders
Reports First Quarter 2026 Financial Results and Recent Business Highlights
REVOLUTION Program & Measles April 9, 2026
Annual Report to Security Holders
Investor Presentation
Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Free Writing Prospectus